Jessica Fye
Stock Analyst at JP Morgan
(4.01)
# 493
Out of 4,883 analysts
189
Total ratings
55.46%
Success rate
9.41%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $90 → $111 | $96.79 | +14.68% | 8 | Jul 8, 2025 | |
| ONC BeOne Medicines | Maintains: Overweight | $317 → $321 | $245.07 | +30.98% | 2 | Jun 27, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $48 | $41.58 | +15.44% | 5 | Jun 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $330 → $338 | $324.27 | +4.23% | 6 | Jun 12, 2025 | |
| MRNA Moderna | Maintains: Underweight | $33 → $26 | $33.17 | -21.62% | 13 | May 22, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $120 → $116 | $111.61 | +3.93% | 11 | May 22, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $512 → $515 | $467.09 | +10.26% | 8 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $10 → $13 | $8.88 | +46.40% | 6 | May 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $245 | $172.53 | +42.00% | 12 | May 2, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $355 → $350 | $296.77 | +17.94% | 16 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $68 | $68.21 | -0.31% | 6 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $58 | $55.44 | +4.62% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $32.49 | +53.92% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $17.37 | +61.20% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $110.50 | +89.14% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.48 | +65.75% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $58.89 | +85.09% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $29.49 | -11.82% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $12.85 | +133.46% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $29.26 | +84.55% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $49.59 | -21.36% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $12.07 | +7.71% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $21.94 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $6.80 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.22 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $16.79 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $37.15 | +104.58% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.82 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.37 | +1,505.84% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.91 | +673.48% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $30.01 | -10.02% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.31 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.12 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.81 | - | 1 | Feb 8, 2018 |
Insmed
Jul 8, 2025
Maintains: Overweight
Price Target: $90 → $111
Current: $96.79
Upside: +14.68%
BeOne Medicines
Jun 27, 2025
Maintains: Overweight
Price Target: $317 → $321
Current: $245.07
Upside: +30.98%
Ionis Pharmaceuticals
Jun 12, 2025
Maintains: Neutral
Price Target: $45 → $48
Current: $41.58
Upside: +15.44%
Alnylam Pharmaceuticals
Jun 12, 2025
Maintains: Overweight
Price Target: $330 → $338
Current: $324.27
Upside: +4.23%
Moderna
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $33.17
Upside: -21.62%
BioNTech SE
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $111.61
Upside: +3.93%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $512 → $515
Current: $467.09
Upside: +10.26%
BioCryst Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.88
Upside: +46.40%
Ascendis Pharma
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $172.53
Upside: +42.00%
United Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $355 → $350
Current: $296.77
Upside: +17.94%
Apr 21, 2025
Maintains: Neutral
Price Target: $70 → $68
Current: $68.21
Upside: -0.31%
Apr 21, 2025
Maintains: Neutral
Price Target: $55 → $58
Current: $55.44
Upside: +4.62%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $32.49
Upside: +53.92%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $17.37
Upside: +61.20%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $110.50
Upside: +89.14%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.48
Upside: +65.75%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $58.89
Upside: +85.09%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $29.49
Upside: -11.82%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $12.85
Upside: +133.46%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $29.26
Upside: +84.55%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $49.59
Upside: -21.36%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $12.07
Upside: +7.71%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $21.94
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $6.80
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $16.79
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $37.15
Upside: +104.58%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.82
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.37
Upside: +1,505.84%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.91
Upside: +673.48%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $30.01
Upside: -10.02%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.31
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.12
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $7.81
Upside: -